2023-04-27T09:57:50-05:00 2022-06-30 363321958 Desmond & Ahern Ltd 10827 S Western Avenue Chicago IL 60643 990 2021-07-01 366009467 Orthopaedic Research and Education Foundation ORTH 8476989980 9400 W Higgins Road 215 Rosemont IL 60018 Andrew N Pollak MD Treasurer 8476989980 2023-04-27 1 Andrew Pollak MD 999009999 Jason L Gierhahn P02385275 7737794720 2023-04-27 3 AAL1 IAL1 2021 2023-04-26 12:10:37Z OREF Thomas P Sculco MD 9400 W Higgins Road 215 Rosemont IL 60018 8006456 0 X www.oref.org X 1955 IL Improving lives by supporting excellence in orthopaedic research. 21 21 12 100 0 0 2959720 3690278 0 0 895658 282163 0 0 3855378 3972441 1144615 1365339 0 0 1712035 1937084 0 0 942806 651305 960907 3507955 4263330 347423 -290889 25903586 22322488 4144211 3875690 21759375 18446798 The Orthopaedic Research and Education Foundation (OREF) mission is improving lives by supporting excellence in orthopaedic research. OREF's vision is that it will be the leader in supporting orthopaedic research to improve function, eliminate pain and restore mobility. 0 0 2715737 1365339 1365339 Grant program: The purpose of OREF is to support research into the causes and treatment of musculoskeletal diseases and injuries. OREF's niche is supporting surgeon-researchers and PHD-researchers in basic science/translation, clinical, and health services research. OREF's education program offers new orthopaedic medical researchers the opportunity to develop their research interests and skills. Through educational programming, OREF supports emerging talent to help them successfully pursue research careers. 2715737 1 1 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 11 0 1 12 1 0 0 0 0 0 0 0 0 0 0 0 0 X 21 21 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AK AL AR AZ CA CT DC DE FL GA IL IN KS KY LA MA MD ME MI MS MN MO MT NC ND NE NH NM NY OH OK OR PA RI SC SD TN UT VA WA WI WV WY X X Rhonda Dirr and Lee Grossman 8476989980 9400 W Higgins Road Rosemont IL 60018 Richard F Kyle MD President 5.00 X X 0 0 0 Joshua J Jacobs MD Treasurer 5.00 X X 0 0 0 Jeffrey S Abrams MD Chair, Corporate Advisory 5.00 X 0 0 0 Francis Y Lee MD PhD Chair Grants 5.00 X 0 0 0 Richard F Santore MD Chair-Individual Developme 5.00 X 0 0 0 Mary Lloyd Ireland MD Trustee 5.00 X 0 0 0 Michael M Chau MD PhD Trustee 5.00 X 0 0 0 Thomas P Sculco MD President-elect 5.00 X X 0 0 0 John D Kelly IV MD Trustee 5.00 X 0 0 0 Jeremie M Axe MD Trustee 5.00 X 0 0 0 B Sonny Bal MD JD MBA PhD Trustee 5.00 X 0 0 0 Nicholas M Bernthal MD Trustee 5.00 X 0 0 0 Eric V Dremel Trustee 5.00 X 0 0 0 Michael P Bolognesi MD Trustee 5.00 X 0 0 0 Karen L Hackett Trustee 5.00 X 0 0 0 James R Ficke MD Trustee 5.00 X 0 0 0 David C Templeman MD Trustee 5.00 X 0 0 0 Stuart Weinstein MD Trustee 5.00 X 0 0 0 Andrew N Pollak MD Trustee 5.00 X 0 0 0 Annunziato Amendola MD Trustee 5.00 X 0 0 0 Daniel J Berry MD Trustee 5.00 X 0 0 0 Evalina Burger-Van der Walt MD Trustee 5.00 X 0 0 0 Lee Grossman CEO 40.00 X 283853 0 47041 Deborah Cummins VP of Research and Grants 40.00 X 129219 0 39276 Edward Hoover Senior VP of Development 40.00 X 151318 0 37959 Karen Pubentz Sr. Director of Communicat 40.00 X 129108 0 27282 John Johnson Campaigns Director 40.00 X 103088 0 10532 Dan Krupp Corporate Relations/Innovation & Partnership Dev 40.00 X 143818 0 13640 940404 0 175730 6 0 1 0 0 3690278 145981 3690278 544505 544505 3771673 4034015 -262342 -262342 -262342 3972441 0 0 282163 1365339 1365339 375571 41313 214075 120183 1169170 669029 124759 375382 89736 48395 12536 28805 201822 105853 31193 64776 100785 47453 20997 32335 56094 26411 11686 17997 580 580 19715 19715 38750 19375 19375 104357 68096 1461 34800 71071 24177 29092 17802 146532 68992 30527 47013 140313 32930 64461 42922 28770 7870 8580 12320 229321 115158 3226 110937 12661 5961 2638 4062 88689 69385 7600 11704 Bad debt 16066 16066 Dues and subscriptions 7988 5595 2393 4263330 2715737 604787 942806 271 231 2762829 3764516 1256334 1075865 69083 91304 181754 156179 38236 25575 16546668 12757300 5230165 4607697 25903586 22322488 169669 194009 3299365 3062602 675177 619079 4144211 3875690 X 112873 -239896 21646502 18686694 21759375 18446798 25903586 22322488 X -290889 -2386372 -635316 X X 0 1 X 1 0 X 5448193 3198011 3932349 2959720 3690278 19228551 5448193 3198011 3932349 2959720 3690278 19228551 3328585 15899966 506240 441988 467531 389234 544505 2349498 21578049 0.73690 0.79210 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 X 13241439 6579 -2143996 542628 10561394 10199908 7026 3592759 558254 13241439 7961755 13785 -82175 19900 7873465 8311807 35531 733712 1119295 7961755 8014335 46789 250683 8311807 0 0 50447 41622 8825 67282 51980 15302 64025 62577 1448 25575 Charitable Remainder Trust Receivable 2741196 Cash Surrender Value of Life Insurance 1853917 Other receivables 12584 4607697 Due to Orthopaedic Partners 619079 619079 X 968213 -2386372 -617856 -3004228 3972441 0 3972441 4280790 17460 17460 4263330 0 4263330 Part IV, Line 2b: On behalf of other orthopaedic organizations, the Foundation accepts contributions for which it performs recordkeeping and provides grants requested by those organizations. Part X, Line 2: FIN 48 Note from Audited Financial Statements: The Foundation, an Illinois nonprofit corporation, is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code and applicable state law, except for taxes pertaining to unrelated business income, if any. The Foundation's annual information and income tax returns filed with the federal and state governments are subject to examination generally for three years after they are filed. The Foundation has adopted the requirements for accounting for uncertain tax positions and management has determined that the Foundation was not required to record a liability related to uncertain tax positions as of June 30, 2022. Part XI, Line 2d - Other Adjustments: Change in cash surrender value of life insurance policies 7,116. Change in charitable remainder trust receivable -624,972. Part XII, Line 2d - Other Adjustments: Orthopaedic partner endowment distribution 17,460. 1 Duke University School of Medicine Suite 820 Erwin Square 2200 West Main Street Durham NC 27705 560532129 50000 0 Quantitative MRI of Glenohumeral Cartilage & Labrum in Shoulder Instability Miller School of Medicine of the University of Miami 1320 South Dixie Highway Suite 650 Locater Code 2960 Coral Gables FL 33146 590624458 300000 0 Glucose Variability and TJA: Continuous Glucose Monitoring Using Dexcom G6 Steadman Philippon Research Institute 181 W Meadow Dr Suite 1000 Vail CO 81657 880245022 99999 0 Understanding Contribution of Senescent Cells to Rate of Fracture Repair The Board of Trustees of the Leland Stanford Junior University 485 Broadway St Redwood City CA 94063 941156365 20000 0 RENEWAL(2): Developing and Testing a Tool for Preference Elicitation in CTS The University of Iowa Office of the Vice President for Research Division of Sponsored Prog Iowa City IA 52242 426004813 49378 0 Platelet Rich Plasma for Osteoarthritis: Role of Exosomes in Effectiveness University of Maryland Baltimore 620 W Lexington Street 4th Floor Baltimore MD 21201 526002033 10000 0 Development of a Patient Specific Cartilage Graft Using MRI and 3D Printing. Perioperative Patient Education and Sling Compliance after Shoulder Surgery. Washington University in StLouis Campus Box 1054 One Brookings Drive St Louis MO 63130 430653611 330000 0 Biologic Age Versus Chronologic Age in ASD: A Prospective Cohort Study. Wearable Sensors to Measure Function after Brachial Plexus Reconstruction. Mediators of the OA Cascade in the Pre-arthritic Hip. KLF10 as a Novel Therapeutic Target in Osteoarthritis. Epigenetic Regulation of Key Molecular Players in the Progression of Hip OA. Yale University 47 College StreetSuite 203 PO Box 208047 New Haven CT 06520 060646973 320000 0 Personal Surgical Planning to Avoid THA dislocation: concept of safe zone. Developing biomarkers for diagnosis and prognosis of orthopaedic infection. Part I, Line 2: The Research Grants Committee is responsible for allocating research funding to advance research in the specialty of orthopaedics and is empowered to establish criteria for the allocation and distribution of philanthropic funds to advance research in the specialty of orthopaedics, implement and conduct independent peer review process to select research funding recipients, prepare and distribute necessary promotional information and application forms for research grants and awards and to accept and allocate or decline to allocate, at its sole and absolute discretion, grants and awards for research. One-year grant recipients receive 50% of the funds to start, then 40% after a six-month financial report is received. A final scientific and lay report within 60 days after the grant ends along with a final financial report is required. Once OREF has the final reports the remaining 10% of the funds are released. One-time award/educational grant/lectureship grants receive full payment after they are approved. Documentation is in the file for lectureships, educational programs and awards. Two or three-year grants are paid and spread over the term of the grant. 10% is withheld until all of the reports are received. Multi-year grant recipients submit annual scientific reports which are then reviewed by the original peer review committee member. X X 0 0 0 0 0 0 0 0 0 Lee Grossman CEO 283853 0 0 0 0 0 17029 0 30012 0 330894 0 0 0 Edward Hoover Senior VP of Development 151318 0 0 0 0 0 12531 0 25428 0 189277 0 0 0 Deborah Cummins VP of Research and Grants 129219 0 0 0 0 0 11355 0 27921 0 168495 0 0 0 Dan Krupp Corporate Relations/Innovation & Par 143818 0 0 0 0 0 8422 0 5218 0 157458 0 0 0 Karen Pubentz Sr. Director of Communicat 129108 0 0 0 0 0 10943 0 16339 0 156390 0 0 0 X 640 145981 FMV 0 0 0 Part I, Column (b): 640 shares of various stock. Form 990, Part VI, Section B, line 11b The Finance Committee reviewed and approved the Form 990. It was provided to the Board of Directors, who had an opportunity to review the return prior to filing. Form 990, Part VI, Section B, line 12c All Trustees annual conflict of interest statements are on file with the OREF CEO. The CEO reviews meeting agendas prior to the meeting and notifies leadership of any issues that need to be addressed before the discussions take place. Any individual who gives notice of a potential conflict is to abstain from participation in discussions related to that item. Form 990, Part VI, Section B, line 15 The Foundation has a formal process to determine the compensation of its CEO. The process includes the following: 1) Review and approval by the Board of Trustees or Compensation Committee; 2) Use of comparable compensation data; 3) Contemporaneous documentation and record keepping. Form 990, Part VI, Section C, line 19 The Foundation made its governing documents, conflict of interest policy, and financial statements available to the public upon request for the period of disclosure set forth in IRC Section 6104(d). Form 990, Part XI, line 9: Orthopaedic partner endowment distribution -17,460. Change in cash surrender value of life insurance policies 7,116. Change in charitable remainder trust receivable -624,972. Form 990, Part XII, line 2c: The process has not changed from the prior year. Charitable Remainder Trusts Charitable trusts IL T 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0